Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Disease patents

      

This page is updated frequently with new Autoimmune Disease-related patent applications.




 Therapeutic agent for autoimmune diseases comprising pd-1 agonist patent thumbnailTherapeutic agent for autoimmune diseases comprising pd-1 agonist
Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients.
Ono Pharmaceutical Co., Ltd.


 Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof patent thumbnailReceptor trem (triggering receptor expressed on myeloid cells) and uses thereof
Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed.
Novo Nordisk A/s


 Compositions comprising bacterial strains patent thumbnailCompositions comprising bacterial strains
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited


 Immunosuppressive blood cells and methods of producing the same patent thumbnailImmunosuppressive blood cells and methods of producing the same
The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .
Universitatsklinikum Heidelberg


 Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases patent thumbnailCompositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (mmp9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.. .
Gilead Sciences, Inc.


 Methods of treating autoimmune disease using a domain antibody directed against cd40l patent thumbnailMethods of treating autoimmune disease using a domain antibody directed against cd40l
Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (itp), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company


 Anti-cd100 antibodies and methods for using the same patent thumbnailAnti-cd100 antibodies and methods for using the same
Compositions and methods are provided for treating diseases associated with cd100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-cd100 monoclonal antibodies have been developed to neutralize cd100..
Vaccinex, Inc.


 Il22 immunoconjugates patent thumbnailIl22 immunoconjugates
The application relates to a conjugate comprising interleukin-22 (il22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ed-a isoform of fibronectin.
Philogen S.p.a.


 Crystalline forms of a bruton's tyrosine kinase inhibitor patent thumbnailCrystalline forms of a bruton's tyrosine kinase inhibitor
Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc


 Artificial antigen-presenting cells and methods for producing and using the same patent thumbnailArtificial antigen-presenting cells and methods for producing and using the same
Described herein are biomimetic janus particles useful as artificial antigen presenting cells capable of activating t cells in vitro. “bull's eye” ligand patterns mimicking either the native or reverse organization of the t cell immunological synapse are provided on the surface of nano- or micro-sized particles.
Indiana University Research And Technology Corporation


Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases.
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection

The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor b-i, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.. .
Rappaport Family Institute For Research In The Medical Sciences

Metallic gold cluster molecules as therapeutic agents for arthritic animals

A therapeutic method for attenuating symptoms of inflammation and autoimmune diseases. This method includes preparing and administering to animals intraperitoneally or orally a metallic gold cluster complex preparation..

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan sulfate mediated macropinocytosis

Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences

Substituted bicyclic compounds

And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Oligonucleotide targeted to the a20-three prime untranslated region

An antisense oligonucleotide comprising a sequence targeted to the 3′ untranslated region (3′ utr) of the tnfaip3 (a20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.. .

Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.

Treatment of il-17 mediated disease by blocking sefir-sefir interactions

A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.

Modulators of ror-gamma receptors, composition and use thereof

The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ror-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of t cells, or treating a disease related to th17 cell responses in a subject.

Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Cell populations having immunoregulatory activity, isolation and uses

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .

Cell populations having immunoregulatory activity, isolation and uses

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
University Of Connecticut

Altering gene expression in modified t cells and uses thereof

The present invention relates to compositions and methods for generating a modified t cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of tcr α chain, tcr β chain, beta-2 microglobulin and fas further comprising a nucleic acid encoding a modified t cell receptor (tcr) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (car). Also included are methods and pharmaceutical compositions comprising the modified t cell for adoptive therapy and treating a condition, such as an autoimmune disease..
The Trustees Of The University Of Pennsylvania

Rna polymerase i inhibitors and uses thereof

Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.. .
Tel Hashomer Medical Research Infrastructure And Services, Ltd.

Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex.
Ibc Pharmaceuticals, Inc.

Immune system modulation for prophylaxis and treatment of diseases and disorders

The invention is directed to biological response modifiers (brm) which may contain one or more compounds, and to methods for enhancement of an immune system with brms of the invention including augmenting a specific immune response either prophylactically or for treatment, as an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an immune system generally. The invention is also directed to the reduction of an unrestrained or improper inflammatory response and/or an immune response such as to treat or prevent autoimmune diseases and disorders, and associated symptoms.
Marpe Holdings, Llc

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of btk, mtor kinase, and bcl-2 or their signaling pathways, and immunomodulatory drugs.
Zhejiang Dtrm Biopharma Co. Ltd.

Cholix toxin-derived fusion moelcules for oral delivery of biologically active cargo

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the vibrio cholera cholix gene (ntcholix), a variant of cholix truncated at amino acid a386 (cholix386) and the use of other various cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.
Applied Molecular Transport, Llc

Novel compositions and therapeutic methods

The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (ra), atherosclerosis, inflammatory bowel diseases (ibd), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection.. .
Ayuvis Research Llc

Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation

Bioassay for the early detection of autoimmune diseases

Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a biological sample that is not a tear sample from the mammal with an antibody that specifically binds to a first polypeptide selected from the group ctss, ctsh, ctsr, ctsw, ctsz, ifng, il-6ra, il-10, il-10ra, il-15, tnfa, apo-f, or lcn-2 or a second polypeptide selected from the group lactoperoxidase, lactoferrin or lysozyme under conditions favoring the formation of an antibody-polypeptide complex, and determining the amount of complex formed, wherein an increased formation of antibody-first-polypeptide complex or a decreased formation of antibody-second-polypeptide complex as compared to a suitable control, indicates a likely positive diagnosis of an autoimmune disease for the mammal, thereby aiding in the diagnosis. Methods of treating the autoimmune diseases are also provided..

Humanized anti-cd22 antibody

Disclosed are humanized rfb4 antibodies or antigen-binding fragments thereof. Therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease.
Immunomedics, Inc.

Benzazepine sulfonamide compounds

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof

The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target auto-reactive immune components for treating and/or preventing the autoimmune diseases associated therewith. The nanoparticles can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune regulation..
The Regents Of The University Of California

Therapeutic uses of cd137pos regulatory t cells in treating autoimmune diseases

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells and a pharmaceutically-acceptable carrier..
University Of Cincinnati

Pharmaceutical compositions comprising soluble cd137

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells and a pharmaceutically-acceptable carrier..
University Of Cincinnati

Methods for treating gi syndrome and graft versus host disease

We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic t lymphocyte (ctls)-induced killing and by damage to endothelial microvasculture, including radiation-induced gi syndrome, graft vs. Host diseases, inflammatory diseases and autoimmune diseases.
Board Of Regents, The University Of Texas System

Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide

Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide..

Methods of treating autoimmunity

Methods of treating, ameliorating, or inhibiting the development of autoimmune diseases by modulating the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease. The binding may be modulated by the administration of d-α-methyldopa, or pharmaceutical compositions comprising therapeutically effective amounts of d-α-methyldopa..
The Regents Of The University Of Colorado, A Body Corporate

Peptide microarrays and novel biomarkers for celiac disease

The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers..
Vibrant Holdings, Llc

Intracellular osteopontin regulates the lineage commitment of lymphoid subsets

Methods for diagnosing and prognosing autoimmune diseases and t cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (opn-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor bcl6, which is involved in t cell activation/differentiation.
Dana-farber Cancer Institute, Inc.

Fused amino pyridine as hsp90 inhibitors

The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
Curis, Inc.

Indole compounds and pharmaceutical use thereof

Wherein each symbol is as described in the specification. The invention also provides a method for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like in a mammal by administering the compound or pharmaceutically acceptable salt thereof or solvate thereof to the mammal..

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease

Disclosed are methods, compositions and uses of concentrated formulations of anti-cd74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (sle).
Immunomedics, Inc.

Method and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases

The present invention relates to the use of one or more mhc class i molecules dextramers (dextramers®) associated with peptides corresponding to apoptotic epitopes of human cd8+ t cells for the predictive prognosis of responsiveness or non-responsiveness to treatments and/or for monitoring the therapeutic effectiveness of treatments with biological medicaments that block and/or inhibit tnf, and/or biological medicaments that block and/or inhibit cytokines or cytokine receptors and/or biological medicaments against b cells and/or biological medicaments that inhibit t cell co-stimulation in patients affected by autoimmune diseases, together with methods and kits for said predictive prognosis.. .
Universita' Degli Studi Di Roma "la Sapienza"

Oral administration of an anti-cd20 antibody for treatment of autoimmune disease

The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of an anti-cd20 antibody is administered to the subject.

Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory t cells (treg) populations; for treating or ameliorating a vascular inflammation, and kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (wig) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a t cell mediated pediatric vasculitis; kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or juvenile idiopathic arthritis; a neoplastic hematological disorder, or a leukemia..
The Regents Of The University Of California

Indole carboxamide compounds

Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis and treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis

The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, crohn's disease and ulcerative colitis (uc).. .
Industrial Technology Research Institute

Methods and compositions for modified t cells

The present invention relates to compositions and methods for generating modified cells with nucleic acid encoding a t cell receptor (tcr), a nucleic acid encoding a bispecific antibody, affinity molecule chimeric receptor, bispecific affinity molecule, or a chimeric ligand engineered activation receptor (clear). One aspect includes a method for generating a modified t cell.
The Trustees Of The University Of Pennsylvania

Fgl2 expressing regulatory t cells

This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory t cells (treg) and associated compositions for the induction of immune tolerance are described.
Veritas Therapeutics Inc.

Therapeutic detoxification compositions and methods of making and using same

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.. .
Immutrix Therapeutics, Inc.

Treatments for autoimmune disease

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases.
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board,of The College Of The Holy

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule.
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Novel imidazopyridazine compounds and their use

This disclosure provides novel imidazopyridazine compounds of formula (i) and pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their practical effect in inhibiting pi3k and potential use in treating a disease responsive to inhibition of pi3k, for example, an inflammatory disease, autoimmune disease or cancer.. .
Hutchison Medipharma Limited

Probiotic bifidobacterium adolescentis strains

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases

The embodiments herein relate to a therapeutic method for the treatment of parkinson disease, other neurodegerative disorders, and autoimmune diseases. The method includes providing sodium thiosulfate through any method of administration (orally, intravenously, through inhalation, intravesically, vaginally, rectal route, sublingually, ophthalmically, or topically) and is given with one or more pharmaceutically acceptable carriers or excipients.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Modulation of ptpra to treat arthritis

Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (pt-pra) antagonist.. .
The Regents Of The University Of California

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
Biogen Ma, Inc.

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Targeted delivery of tertiary amine-containing drug substances

Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed..
Seattle Genetics, Inc.

(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability

The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
Sanofi

Concentrated methotrexate solutions

Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh

Anti-pd-1 monoclonal antibody and obtaining method therefor

The invention provides human monoclonal antibodies that specifically bind to pd-1 with high affinity. The anti-pd-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed.
Beijing Jingyitaixiang Technology Development Co., Ltd.

Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human cd28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody.
Bristol-myers Squibb Company

Modulating gamma-c-cytokine activity

Peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Y is c, n or s.. .

Compounds that expand hematopoietic stem cells

The present invention relates to compounds and compositions for expanding the number of cd34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (hscs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense..
Novartis Ag

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions

Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.

Methods and kits for screening transplant recipients and candidates

Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease.
National Institute Of Transplantation Foundation

Antibodies specific for mmp9

The present invention relates to new proteins that bind to mmp9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the mmp9 binding proteins according to the invention are able to neutralize mmp9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers.
Merck Patent Gmbh

Anti-cd40 antibodies and uses thereof

Antibodies and antibody fragments that bind to human cd40 and inhibit interaction between cd40 and its ligand, cd40l are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of b or t cells and treat or prevent disorders such as autoimmune diseases..
Biogen Ma Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Flt3 receptor antagonists

The invention pertains to novel flt3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases..
UniversitÉ De Strasbourg

Soluble mediator

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
The Walter And Eliza Hall Institute Of Medical Research

Aza-heteroaryl compounds as pi3k-gamma inhibitors

And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Treatment of ocular inflammatory diseases using laquinimod

Disclosed is a method for treating an ocular inflammatory disease (oid), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Teva Pharmaceutical Industries, Ltd.

Supporting immunomodulatory agent

The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing c3-c8 carboxylic acids, their physiologically tolerable salts and/or esters with c1-c8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.. .
Flexopharm Brain Gmbh & Co. Kg

Aptamers for use against autoantibody-associated diseases

The present invention relates to new aptamer molecules for use in the treatment and/or diagnosis of autoimmune diseases associated with autoantibodies against g-protein coupled receptors, a pharmaceutical composition comprising such aptamer molecules, an apheresis column comprising such aptamer molecules and a method for the determination of nucleotide sequences for use as sequences of aptamer molecules.. .
Berlin Cures Holding Ag

Antibody therapeutics that bind cd137

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

An anti-cd45rc antibody for use as drug

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use in expanding and/or potentiating regulatory t cells..
UniversitÉ De Nantes

Therapeutic use of anti-cd22 antibodies for inducing trogocytosis

Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention.
Immunomedics, Inc.

Modified peptides and their use for treating autoimmune diseases

The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications.. .
Immupharma France Sa

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Discovery of regulatory t cells programmed to suppress an immune response

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (il-15r) agonists in an amount effective to ameliorate a symptom of the autoimmune disease.
Dana-farber Cancer Institute, Inc.

Tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation

Methods of treating inflammatory and autoimmune diseases and disorders

Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder.
Yale University

Her2/neu-specific antibodies and methods of using same

This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Immunoglobulin constant region fc receptor binding agents

Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function.
Gliknik Inc.

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution

Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases

A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Use of pdl1 expressing cells to convert t cells into regulatory t cells

The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Antibody binding to fcrn for treating autoimmune diseases

The present disclosure relates to an isolated anti-fcrn antibody, which is an antibody binding to fcrn (stands for neonatal fc receptor, also called fcrp, fcrb or brambell receptor) that is a receptor with a high affinity for igg or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The fcrn-specific antibody according to the present disclosure binds to fcrn non-competitively with igg to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.

Antibody binding to fcrn for treating autoimmune diseases

The present disclosure relates to an isolated anti-fcrn antibody, which is an antibody binding to fcrn (stands for neonatal fc receptor, also called fcrp, fcrb or brambell receptor) that is a receptor with a high affinity for igg or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The fcrn-specific antibody according to the present disclosure binds to fcrn non-competitively with igg to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.

Composition containing smad protein for treatment of autoimmune diseases, a fusion protein comprising smad protein, an expression vector and a preparing the same

The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.. .

Pegylated interferon-beta variant

The present invention provides a pegylated ifn-β variant and a composition for preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases, the composition comprising the pegylated ifn-β variant as an effective ingredient. The pegylated ifn-β variant of the present invention has an excellent anti-viral efficacy, immune regulatory function and anti-cell growth efficacy by virtue of better pharmacokinetic properties compared to native ifn-β and non-pegylated ifn-β variants, and therefore can be used usefully against various diseases.
Abion Inc.

Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same

The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and pge2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of nr4a2 and/or ubash3b at gene or protein are increased more than 2-fold compared to the immature dendritic cells in addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy..
Jw Creagene Inc.

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Molecules with specificity for cd45 and cd79

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen cd45 and a binding domain specific to the antigen cd79a and/or cd79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.. .
Ucb Biopharma Sprl

Anti-ilt7 antibody

An antibody binding to ipc was obtained by using an animal cell in which a cell membrane protein associatable with ilt7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ilt family molecules and ilt7.
Sbi Biotech Co., Ltd.

Molecules with specificity for cd79 and cd22

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen cd22 and a binding domain specific to the antigen cd79a and/or cd79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.. .
Ucb Biopharma Sprl

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein using a linker. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity

The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of il-34 in a biological sample obtained from said patient, wherein the presence of il-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies..
UniversitÉ De Nantes

Small molecule inhibitors of stat3 with anti-tumor activity

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s3i-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
University Of Central Florida Research Foundation.

Marker sequences for diagnosing and stratifying systemic sclerosis patients

The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; ssc) and to the markers identified with the aid of this method, which can differentiate between ssc and other autoimmune diseases on the one hand and between different ssc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of ssc.
Protagen Ag

Compositions and methods for the diagnosis of systemic autoimmune disease

The present disclosure relates to the field of molecular biology and immunology. More specifically, the present disclosure provides compositions and methods for detecting anti-th/to autoantibodies in the serum of subject with a systemic autoimmune disease, such as systemic sclerosis (ssc)..
Inova Diagnostics, Inc.

Methods of using cells associated with autoimmune disease

The present invention relates to methods of diagnosing autoimmune disease, predicting suitable treatments of autoimmune disease or identifying autoantigens of autoimmune disease using a population of immunogenic hla-dr+ t cells.. .
Singapore Health Services Pte Ltd.

Novel combinations for antigen based therapy

The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject the subject may have a serum vitamin-d level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, and to composition comprising i) at least one beta cell autoantigen, and at least one of iia) an il-10 inducing compound selected from the group consisting of vitamin-d, vitamin-d analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve cd4+ tcells, such as a cyclooxygenase inhibitor, a ctla-4 compound or a tnf alpha inhibitor.
Diamyd Medical Ab

Mth1 inhibitors for treatment of inflammatory and autoimmune conditions

A compound of formula (i), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.. .
Thomas Helledays Stiftelse For Medicinsk Forskning

Treatment of autoimmune disease

Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole pkc inhibitors..
Mingsight Pharmaceuticals, Inc.

Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

The specification provides compositions comprising chimeric proteins comprising aat conjugated to an fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., type 1 and type 2 diabetes, are also provided..
Beth Israel Deaconess Medical Center, Inc.

Pyridine and pyridimine compounds as pi3k-gamma inhibitors

The present disclosure provides compounds of formula i, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .
Incyte Corporation

Use of kukoamine a and kukoamine b

The use of kukoamine a and kukoamine b in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (lps) and unmethylated dna (cpg dna) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use and directionally isolates lead compounds from traditional chinese medicine.
The First Affiliated Hospital, Third Military Medical University, Pla

Dd1alpha receptor and uses thereof in immune disorders

Described herein are methods and compositions for treatment of immune-related diseases or disorders by modulating dd1α activity, alone or in combination with modulation of pd-1 activity. In some embodiments, the methods and compositions described herein are directed to treatment of cancer and/or infections (e.g., bacterial infection, and/or fungal infection).
The General Hospital Corporation

Compositions and methods for autoimmune disease

Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (scnp), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.. .
Nodality, Inc.

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Pyrrolopyrimidine compounds and their uses

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases.
Astex Therapeutics Ltd.

Autoantibody detection method, testing possibility of autoimmune disease contraction, autoantibody detection reagent, and autoimmune disease test reagent

The present invention provides an autoantibody detection method that can detect an autoantibody causing an autoimmune disease with high accuracy. The autoantibody detection method of the present invention includes the steps of; causing a sample and an antigen reagent comprising a denatured protein presented by an mhc class ii molecule to come into contact with each other; and detecting a complex of an autoantibody in the sample and the denatured protein in the antigen reagent.
Osaka University

Self assembling nucleic acid nanostructures

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.

Bi-terminal pegylated integrin-binding peptides and methods of use thereof

The present invention provides bi-terminal pegylated peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the peg moieties.
The Regents Of The University Of California

Quinoxaline compounds and uses thereof

This invention provides compounds of formula i and subsets thereof: wherein t, j, r, r4, rq, o, ra, and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, or t-cell mediated autoimmune disease..
Millennium Pharmaceuticals, Inc.

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds described herein, such as of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Binding molecules specific for il-21 and uses thereof

This disclosure provides il-21 binding molecules, e.g., anti-il-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-il-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof.
Boston Pharmaceuticals Inc.

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity

The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
University-industry Cooperation Group Of Kyung Hee University

Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory t cells

The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory t cells (treg) in an organism and various methods in which the agents according to the invention are used.. .
Aicuris Gmbh & Co. Kg

Har-nds-derived stem cells, separating same, and use thereof

The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from har-nds, adult stem cells ndscs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases..
Eutilex Co., Ltd

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.
Platform Brightworks Two, Ltd.

Benzo lipoxin analogues

Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation..
University Of Southern California

Canine autoimmune conditions and diagnosis and treatment thereof

The disclosure includes methods of identifying a dog at risk of developing a an autoimmune disease or condition, for example a hypothyroid disease or condition, comprising testing whether the dog exhibits one or more selected single nucleotide polymorphisms (snps), together with diagnostic kits for carrying out such methods, methods of treatment or prophylaxis of such autoimmune disease or condition, e.g., comprising administering an effective amount of tea extract to a dog in need thereof, and a canine diet or supplement comprising tea extract, useful for treatment of prophylaxis of such autoimmune disease or condition, or for maintenance of thyroid health in a dog.. .
The Translational Genomics Research Institute

Humanized antibodies against cd269 (bcma

The invention relates to humanized antibodies or antibody fragments that bind cd269 (bcma), thereby disrupting the interaction between cd269 and its native ligands (baff and april), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.. .
Max-delbruck-centrum Fur Molekulare Medizin In Der Helmholtz-gemeinschaft

O-glcnac transferase (ogt) inhibitors and uses thereof

The present invention provides inhibitors of o-glcnac transferase. Typically, the inhibitors are quinolinone-6-sulfonamides.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Methods to treat diseases with protein, peptide, antigen modification and hemopurification

The current invention discloses methods to modify protein and peptide and antigen to treat disease such as pathogen infection, autoimmune diseases and cancer. The method involves increasing the molecular weight of the protein by connecting multiple peptide units with site specific conjugation to extend the in vivo half life.

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity

The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
University-industry Cooperation Group Of Kyung Hee University

Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory t cells

The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory t cells (treg) in an organism and various methods in which the agents according to the invention are used.. .
Aicuris Gmbh & Co. Kg



Autoimmune Disease topics:
  • Autoimmune Disease
  • Immune Disease
  • Autoimmune
  • Autoimmune Diseases
  • Immune Diseases
  • Transplant
  • Infectious Disease
  • Infectious
  • Inflammatory Disease
  • Antagonist
  • Rheumatoid Arthritis
  • Proliferative
  • Nucleotide
  • Antibodies
  • Infectious Diseases


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3906

    file did exist - file did put14029

    4 - 1 - 255